The following trials provide information to treat various types of disease of the brain and the central and local nervous systems, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A Phase I, Double-blind, Randomized, Placebo-controlled', Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD5213 After Administration of Multiple Ascending Doses for 10 Days in Healthy Male and Non-fertile Female Volunteers
- collapse Effectiveness of atypical antipsychotics on anhedonic features in patients with schizophrenia
- collapse A Randomised, Double-blind, Placebo-controlled, Parallel Design, Multicentre Study in Patients With Mild to Moderate Alzheimer's Disease to Investigate the Effect on Cognitive Function as Measured by Repeated CogState Testing in Relation to Effects on Traditional Cognitive Measures After 12 Weeks
- collapse Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment
- collapse A Multicenter, Randomized, Double-Blind Parallel Group Placebo-Controlled Phase III,Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
- collapse A Single-centre, Double-blind, Double-dummy, Randomised, Placebo-controlled, Four-period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600 mg and 150 mg) on QT/QTc Interval, Compared to Placebo, using Moxifloxacin (Avelox) as a Positive Control, in Healthy Male Volunteers
- collapse KvaliMed - a Qualitity Project With Focus on Patients in Antipsycotic Treatment
- collapse A study evaluating the treatment selection and outcome when changing antipsychotic treatment in schizophrenic patients.
- collapse Epidemiological observational non-interventional study to research the prevalence of bipolar criteria of hospital In-patients with schizophrenia and patients with recurrent depression.
- collapse A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Long-Term Safety and Tolerability Study of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy
